Clinical trials: Coronary Stent Occlusion
Coronary Artery Disease
Resolute Integrity US Extended Length Sub-Study(RI US XL)
Prospective, multi-center, non-randomized, single-arm, open-label study to assess the safety and efficacy of the Resolute Integrity Stent for the treatment of de novo lesions in native coronary arteries with a reference vessel…
- Trial name
- RI-US XL (NCT01913600)
- Testing
- Resolute Integrity Stent
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Medtronic Vascular
Arterial Occlusive Diseases, Myocardial Ischemia
RESOLUTE Japan SVS: The Clinical Evaluation of the MDT-4107 DES in the Treatment of De Novo Lesions in Small Diameter Native Coronary Arteries
The objective of the study is To verify the safety and efficacy of the MDT-4107 Drug-Eluting Coronary Stent in the treatment of de novo lesions in native coronary arteries with a reference vessel diameter (RVD) that allows the…
- Conditions
- Arterial Occlusive Diseases, Myocardial Ischemia, Cardiovascular Diseases, Coronary Artery Disease
- Trial name
- RJ-SVS (NCT01150500)
- Testing
- MDT-4107 Zotarolimus-Eluting Coronary Stent
- Where
- Japan
- Volunteers
- 65 people
- Sponsor
- Medtronic Vascular
Coronary Artery Disease
The Safety and Efficacy of Biolimus in the Treatment of Patients With in Stent Restenosis
This study consisted of a randomized controlled trial group and a long balloon observation group. In the randomized control group, 280 subjects with in-stent restenosis were planned to be recruited and randomly assigned to the…
- Trial name
- NCT04733443
- Testing
- Biolimus, SeQuent® Please Neo
- Where
- China
- Volunteers
- 310 people
- Sponsor
- JW Medical Systems Ltd
Coronary Artery Disease, Coronary Artery Stenosis
A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)
To evaluate the safety and efficacy of the Absorb BVS System compared to the XIENCE V Everolimus Eluting Coronary Stent System (EECSS) in the treatment of subjects with ischemic heart disease caused by up to two de novo native…
- Conditions
- Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
- Trial name
- ABSORB CHINA (NCT01923740)
- Testing
- XIENCE V EECSS, Absorb BVS System
- Where
- United States
- Volunteers
- 480 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1)
XIENCE V USA is a prospective, multi-center, multi-cohort post-approval study. The objectives of this study are To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings, and To…
- Trial name
- XVU-Phase 1 (NCT00676520)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent
- Where
- United States
- Volunteers
- 8,053 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting
The purpose of this study is to provide information of the relative potency of prasugrel and clopidogrel on platelet function studies, inflammation, and myocyte necrosis in subjects undergoing elective percutaneous coronary…
- Trial name
- PRINCIPLE (NCT00357968)
- Testing
- Prasugrel, Clopidogrel
- Where
- 16 sites in United States, France and 2 more
- Volunteers
- 201 people
- Sponsor
- Eli Lilly and Company
Coronary Artery Disease, Myocardial Infarction
Communicational Program "Trust" to Improve Adherence to Medications
The trial was designed in such a way as to show that the proposed program "Trust" increases the proportion of patients who adhere to therapy in the cohort of those with coronary heart disease for two years after successful…
- Conditions
- Coronary Artery Disease, Myocardial Infarction, Cardiovascular Diseases
- Trial name
- NCT03268291
- Testing
- Standard outpatient observation, Communicational program "Trust"
- Where
- Russia
- Volunteers
- 2,000 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Coronary Artery Disease, Acute Coronary Syndrome
Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES
New-generation metallic drug-eluting stents represent the standard of care among patients undergoing percutaneous coronary intervention (PCI).
- Conditions
- Coronary Artery Disease, Acute Coronary Syndrome, Chronic Coronary Syndrome, Myocardial Infarction
- Trial name
- PARTHENOPE (NCT04135989)
- Testing
- Percutaneous coronary intervention with implantation of amphilimus-eluting stents for coronary artery disease., Percutaneous coronary intervention with implantation of everolimus-eluting stents for coronary artery disease., Personalized DAPT duration
- Where
- 13 sites in Italy
- Volunteers
- 2,106 people
- Sponsor
- Federico II University
Coronary Artery Disease, Intracoronary Lithotripsy
Influence of Calcium Pattern on Plaque Modification Achieved With Intracoronary Lithotripsy
Calcified coronary artery disease is a frequently encountered problem that can lead to poorer outcomes for patients undergoing PCI.
- Conditions
- Coronary Artery Disease, Intracoronary Lithotripsy, Optical Coherence Tomography, Percutaneous Coronary Intervention
- Trial name
- NCT04698902
- Testing
- Intracoronary lithotripsy
- Where
- Spain
- Volunteers
- 96 people
- Sponsor
- Fundacion Investigacion Interhospitalaria Cardiovascular
Coronary Artery Disease
Elixir Medical Clinical Evaluation of the Novolimus-Eluting Coronary Stent System: A Randomized Study "EXCELLA II STUDY"
Randomized Study To evaluate the safety and effectiveness of the Elixir Medical DESyne Novolimus-Eluting Coronary Stent System with Durable Polymer through the assessment of clinical, angiographic and IVUS endpoints as compared…
- Trial name
- NCT00792753
- Testing
- Medtronic Endeavor Coronary Stent System, DESyne BD Novolimus Stent System, DESyne Novolimus Stent System
- Where
- 8 sites in Australia, Belgium and 6 more
- Volunteers
- 360 people
- Sponsor
- Elixir Medical Corporation
Coronary Artery Disease
DESTINY TRIAL (Inspiron x Biomatrix)
The main objective of this study is to evaluate the effectiveness of stent Inspiron ™ sirolimus-eluting and coating the abluminal biodegradable stent Biomatrix Flex ™ lesions in native coronary arteries.
- Trial name
- NCT01856088
- Testing
- Inspiron Stent, Biomatrix Flex Stent
- Where
- 10 sites in Brazil
- Volunteers
- 170 people
- Sponsor
- Scitech Produtos Medicos SA
Coronary Artery Disease
The Medtronic Endeavor III Drug Eluting Coronary Stent System Clinical Trial
To demonstrate the equivalency in in-segment late lumen loss at 8 months between the Endeavor Drug Eluting Coronary Stent System coated with ABT-578 (10 micrograms/mm) and the Cypher Sirolimus-Eluting Coronary Stent System for…
- Trial name
- ENDEAVOR III (NCT00217256)
- Testing
- Percutaneous Coronary Stenting
- Volunteers
- 436 people
- Sponsor
- Medtronic Vascular
Coronary Artery Disease
BioFreedom French Registry
Prospective, observational multi-center registry to be conducted at up to 25 French interventional cardiology centers. Patients will be eligible once they have received at least one BioFreedomTM DCS as per standard clinical…
- Trial name
- NCT03745066
- Where
- 6 sites in France
- Volunteers
- 1,500 people
- Sponsor
- Biosensors Europe SA
Coronary Arteriosclerosis
YUKON Choice Versus TAXUS Liberté in Diabetes Mellitus
Revascularisation procedures such as percutaneous coronary intervention are associated with overall worse outcomes in patients with diabetes mellitus.
- Trial name
- NCT00368953
- Testing
- Yukon Choice stent system, Taxus Liberté stent system
- Where
- Germany
- Volunteers
- 240 people
- Sponsor
- University of Leipzig
Stable Angina, Unstable Angina, Silent Coronary Ischemia, Coronary Artery Disease
ISAR-DAPT (A Comparative Evaluation of Efficacy and Safety in the 3-Months DAPT Group vs. the 6-Months DAPT Group of Patients Treated With the Coroflex ISAR Stent; A Prospective, Multicenter, Randomized, Open-Label Clinical Trial)
This clinical trial studies patients treated with the Coroflex ISAR Stent for coronary artery disease in order for the objective of verifying the non-inferiority of results that among patients who were administered DAPT for 3…
- Trial name
- NCT02609698
- Testing
- Coroflex ISAR, 3 months DAPT, 6 months DAPT
- Where
- South Korea
- Volunteers
- 906 people
- Sponsor
- Ajou University School of Medicine
Coronary Artery Disease
"JACTAX" Trial Drug Eluting Stent Trial
Prospective, multi-center, non-randomized registry. 100 patients will be enrolled at up to 10 clinical sites in Europe. The results of this study will be compared to the TAXUS™ ATLAS clinical trial to evaluate the safety of the…
- Trial name
- NCT00754728
- Testing
- JACTAX DES
- Where
- 5 sites in Germany, United Kingdom
- Volunteers
- 103 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease, Atherosclerosis
Assessment of Stent Strut Coverage and Endothelial Function After Drug-Eluting Stents
The purpose of this study is to compare coronary endothelium function in patients with a zotarolimus-eluting versus a sirolimus-eluting or a everolimus-eluting stents with optical coherence tomography, vasoconstriction in…
- Trial name
- ASSESS (NCT01073111)
- Testing
- zotarolimus-eluting stent (ENDEAVOR®), sirolimus-eluting stents (CYPHER SELECT® PLUS), everolimus-eluting stents (PROMUS®)
- Where
- Japan
- Sponsor
- Hyogo Medical University
Coronary Artery Disease
Late-lumen Changes After Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stents in De Novo Coronary Lesions
This study aims to compare late-lumen loss (LLL) between DCB and DES to treat de novo coronary artery stenosis by intravascular ultrasound (IVUS).
- Trial name
- LARGER-DCB (NCT06954714)
- Testing
- Drug-eluting stent implantation, Drug-coated balloon angioplasty
- Where
- 8 sites in South Korea
- Volunteers
- 256 people
- Sponsor
- Chonnam National University Hospital
Coronary Artery Disease
Hybrid Revascularization Observational Study
The purpose of the study is to get a better understanding of patients who have multi-vessel coronary artery disease (blockages in more than one vessel bringing blood to the heart) and have either Hybrid Coronary Revascularization…
- Trial name
- NCT01121263
- Where
- 11 sites in United States
- Volunteers
- 298 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Coronary Artery Disease
The Rolex Registry (Revascularization Of LEft Main With Resolute onyX)
The primary objective of this study is to assess the safety and efficacy of the new-generation zotarolimus-eluting stent Resolute Onyx in the treatment of unprotected left main coronary artery disease (ULMCAD), both isolated or…
- Trial name
- Rolex (NCT03316833)
- Testing
- Resolute Onyx
- Where
- 33 sites in Italy, Portugal
- Volunteers
- 450 people
- Sponsor
- University of Padova